Targeting and Treating MET-Dependent Lung Cancers

Lyudmila Bazhenova, MD, Professor of Medicine at the University of California, San Diego, California, discusses targeted therapy for MET-dependent lung cancers, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer in New York.

In her presentation, Dr Bazhenova covered the currently approved treatment options for patients with MET exon 14 skipping mutations, capmatinib and teporinib, and touched on some of the ongoing clinical trials for treatment options in patients with MET-amplifications, or who have developed MET-resistance.

Transcript

Hi. I'm Dr. Lyudmila Bazhenova. I'm a professor of medicine and thoracic medical oncologist from University of California San Diego. Today, I will be discussing the management of patients with MET exon 14 skipping mutations. In lung cancer, MET can be altered by either increasing amplification or overexpression or a special mutation in MET called MET exon 14 skipping. Currently, we have 2 drugs approved for that indication, which are capmatinib and tepotinib, both currently approved regardless of the line of therapy. The overall response rate in those drugs ranges between 40% to 60%. The median progression-free survival is around 10 months. It is very important to make sure that you test your patient for that mutation and offer them the appropriate therapy.

At this point, we don't know what to do for patients who have a MET amplification or develop MET-resistance as an acquired resistance in the patients with EGFR mutation who have been treated with osimertinib. I have presented some data looking at the efficacy of combining osimertinib plus MET tyrosine kinase inhibitors in MET-amplified secondary-resistant patients, which has some efficacy. This currently does not have an approval. I also presented the data from the VISION trial as well as GEOMETRY trial looking at efficacy of capmatinib and tepotinib in patients with MET amplification. Again, currently this also does not have an FDA approval, so for those patients who have MET resistance to osimertinib or MET amplification, I highly encourage referring those patients to clinical trials so we can learn how those drugs perform in those patient populations.

Source

Bazhenova L. Targeted Therapy for MET-Dependent Lung Cancers. Presented at: Great Debates & Updates in Lung Cancer; October 14-15, 2022; Brooklyn, New York.